Cutoff: 13 October 2026. Consensus supports discovery and checks of specific source aspects; it is not a primary study, a full-paper audit or a causal probability meter.
Observed Consensus calls the NAS composite activity reversal and its minimal-criteria count resolution. Actual Methods define improvement as a three-point NAS drop or NAS at most two; actual Results show assigned NAS/steatosis benefit but nonsignificant assigned inflammation/ballooning differences. This is genuine activity efficacy, not automatically a current inflammation/ballooning resolution result. Original PMID19827166. Access: full_text_partial.
Provider describes an apparent seven-percent loss threshold. Actual Results place the broader component positives in achieved-at-least-seven-percent strata, while the randomized component contrasts were nonsignificant. The weight threshold is nonrandomized association; it is not assigned-dose necessity, a baseline eligibility boundary or justification to exclude nonresponders. Original PMID19827166. Access: full_text_partial.
Provider gives 31 randomized participants and percentages but omits actual endpoint-biopsy availability. Original Results show 28 of 31 with paired biopsy: 18 of 21 lifestyle and all 10 controls. Therefore its 72-versus-30-percent composite is an available-biopsy comparison, not a silent 31-person complete-pathology audit; missingness and small power limit certainty. Original PMID19827166. Access: full_text_partial.
Provider identifies Promrat as the only small randomized lifestyle histology trial. The examined newer original Methods/Results contain a randomized ten-month energy-restriction/HIIT comparison with explicit inflammation/ballooning resolution and activity benefit. Provider corpus omission cannot establish absence. Original Results count nine resolutions but only eight ballooning-zero subjects, an unresolved internal inconsistency; retain qualitative positive without inventing a corrected fraction. Original PMID38914313. Access: full_text_partial.
Provider correctly distinguishes the nonrandomized cohort and larger achieved-loss response. The examined original abstract reports 293 enrolled and 261 paired biopsies with subgroup resolution/regression associations. The follow-up prediction PMID26849287 shares that cohort; different subgroup counts or prediction models do not constitute a new causal trial. No complete cohort body was examined. Original PMID25865049. Access: abstract_metadata.
Provider correctly retains BRAVES surgery superiority. The original trial abstract distinguishes ITT and available-protocol response rates. Lifestyle plus best medical care is a comparator to surgery, so its response percentage cannot establish efficacy versus untreated patients or isolate lifestyle weight mediation. Surgery adverse events remain part of its separate evidence. Original PMID37088093. Access: abstract_metadata.
Provider treats five-year surgery biopsy benefit as distinct from lifestyle and reports incomplete biopsy availability. The examined original abstract supports substantial observed resolution/regression with 64 of 94 five-year-eligible patients biopsied. It is selected uncontrolled long-term surgery, outside the registered 24–104-week lifestyle primary; absence of statistically different observed groups does not rule out unmeasured nonresponse bias. Original PMID32553765. Access: abstract_metadata.
Provider discusses component dissociation largely through older trials and reviews, with recent originals absent from its indexed text. The selected F4 semaglutide original Methods/Results directly show significant weight/MRI-fat reduction but null biopsy resolution/fibrosis at 48 weeks, differential biopsy availability and no decompensation events. This is a stage/drug boundary; it neither proves lifestyle failure nor event prevention from biomarkers. Original PMID36934740. Access: full_text_partial.
Provider explicitly lacks ESSENCE, SYNERGY-NASH and MAESTRO-NASH primary details. Examined original abstracts PMID40305708,38856224,38324483 retain genuine respective clinical-pathology positives. A review search cutoff is not the present evidence cutoff, and those drug effects cannot be borrowed as lifestyle or isolated-weight causal lines. Original PMID40305708. Access: abstract_metadata.
Consensus was used to identify literature and cross-check specific claims about design, endpoints, scope and research gaps. Those aspects were checked against original primary abstracts/status records and selected original Methods/Results passages. Consensus output was not treated as original full text. Provider search omissions are not evidence that a study does not exist. Source access and examination receipts are retained. Scite use or monthly unavailability is recorded per case; provider citation counts do not change causal grades.